Racial disparities in survival trends in patients with metastatic Hormone receptor positive/Her 2 negative breast cancer: a SEER population-based study

被引：0
|
作者：
Soto, Alvaro Alvarez
Bernal, Ana Maria
Mesias, Jesus Anampa
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-03-21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-03-21
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice.
    Wang, Xiaoliang
    Ascha, Mustafa
    Green, Tammy
    Lewin, Heather G.
    Showalter, Timothy N.
    Goldstein, Lori J.
    Calip, Gregory Sampang
    Whitaker, Kristen Danielle
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
    Brezden-Masley, Christine
    Fathers, Kelly E.
    Coombes, Megan E.
    Pourmirza, Behin
    Xue, Cloris
    Jerzak, Katarzyna J.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (02) : 507 - 515
  • [33] A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
    Christine Brezden-Masley
    Kelly E. Fathers
    Megan E. Coombes
    Behin Pourmirza
    Cloris Xue
    Katarzyna J. Jerzak
    Breast Cancer Research and Treatment, 2021, 185 : 507 - 515
  • [34] Effectiveness of platinum-based chemotherapy for hormone receptor-positive HER2-negative metastatic breast cancer
    Uratani, Lucas Fernando
    Bermejo, Francesco Sansone
    Hashizume, Pedro HenriqueShimiti
    Bonadio, Renata Colombo
    Testa, Laura
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Irfan Cicin
    Hakan Karagol
    Ufuk Usta
    Atakan Sezer
    Sernaz Uzunoglu
    Rusen Alas-Cosar
    Tarkan Yetisyigit
    Kazim Uygun
    Medical Oncology, 2009, 26 : 335 - 343
  • [36] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Cicin, Irfan
    Karagol, Hakan
    Usta, Ufuk
    Sezer, Atakan
    Uzunoglu, Sernaz
    Alas-Cosar, Rusen
    Yetisyigit, Tarkan
    Uygun, Kazim
    MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343
  • [37] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
    Lankford, M. L.
    Britton, S. L.
    Buettner, A. D.
    Scharf, M.
    Tiscione, B.
    Willey, J. P.
    Mahtani, R. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer
    Ferro, Antonella
    Campora, Michela
    Caldara, Alessia
    De Lisi, Delia
    Lorenzi, Martina
    Monteverdi, Sara
    Mihai, Raluca
    Bisio, Alessandra
    Dipasquale, Mariachiara
    Caffo, Orazio
    Ciribilli, Yari
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (12)
  • [39] Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status
    Chen, Lu
    Li, Christopher I.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (11) : 1666 - 1672
  • [40] New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients
    Yamamura, Jun
    Kamigaki, Shunji
    Fujita, Junya
    Osato, Hiroki
    Manabe, Hironobu
    Tanaka, Yumiko
    Shinzaki, Wataru
    Hashimoto, Yukihiko
    Komoike, Yoshifumi
    BMC CANCER, 2021, 21 (01)
12345